Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in biologic-naive active psoriatic arthritis
NL-OMON39972Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in psoriatic arthritis (PsA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at Week 24. Started Nov 2013; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON39972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39972.